According to the IMARC Group, the polymyalgia rheumatica market exhibited a market size of US$ 3,287.1 Million in the year 2023 and is projected at a CAGR of 13.06 % during 2024-2034. This can be attributed to the increasing use of subcutaneous sarilumab injection in disease medication since it works by inhibiting the interleukin-6 activity, a substance that promotes inflammation in the body.
Polymyalgia rheumatica is an inflammatory disorder that causes muscle stiffness and pain, particularly in the hips and shoulders. The polymyalgia rheumatica market is expanding rapidly, owing to the rising prevalence of the disease among the aging population, as it primarily affects individuals over 50 years old. Additionally, increasing awareness about early diagnosis and treatment options among both patients and wellness providers is fueling market growth. The availability of corticosteroids, the primary medication for polymyalgia rheumatica, continues to support market expansion, while research into alternative therapies, such as biologics and immunosuppressants, is opening new avenues for treatment. Moreover, the growing healthcare expenditure in developed and developing countries, coupled with supportive government initiatives, is positively impacting the growth of the polymyalgia rheumatica market. In parallel, pharmaceutical companies are investing in research and development to introduce innovative therapies with fewer side effects, improving patient compliance. The increasing adoption of telemedicine, as well as digital health solutions, is also making it easier for patients to access healthcare services, leading to better disease management. Meanwhile, collaborations between research institutions and biotech firms are accelerating the development of targeted therapies for polymyalgia rheumatica. The trend toward personalized medicine, which tailors treatments based on genetic and molecular profiling, is expected to be a key driver in the growth of the polymyalgia rheumatica market in the coming years.
Request for a sample of this report: https://www.imarcgroup.com/polymyalgia-rheumatica-market/requestsample
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country:
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of thePolymyalgia rheumatica market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across thePolymyalgia rheumatica market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the current Polymyalgia rheumatica market drugs and late-stage pipeline drugs.
In-Market Drugs:
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Competitive Landscape with key players:
The competitive landscape of the Polymyalgia rheumatica market has been studied in the report with the detailed profiles of the key players operating in the market.
Ask Analyst for Customization and Explore Full Report with TOC: https://www.imarcgroup.com/polymyalgia-rheumatica-market/toc
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
